Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 8/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501778 | 1.00 | EPHX2 (0.53) | EPHX2BACE1CYP2C9CDK5CDK5R1 | |
| SCHEMBL4493061 | 0.91 | EPHX2 (0.52) | EPHX2BACE1NAMPTFLT3 | |
| SCHEMBL4493057 | 0.91 | EPHX2 (0.52) | EPHX2BACE1NAMPTFLT3 | |
| SCHEMBL4504723 | 0.91 | BACE1 (0.46) | BACE1NAMPTFLT3USP2CYP1A2 | |
| SCHEMBL3847376 | 0.91 | CDK5 (0.47) | EPHX2CYP2C9CDK5CDK5R1NAMPT | |
| SCHEMBL4504719 | 0.91 | BACE1 (0.46) | BACE1NAMPTFLT3USP2CYP1A2 | |
| SCHEMBL226897 | 0.90 | EPHX2 (0.49) | EPHX2BACE1CDK5CDK5R1NAMPT | |
| SCHEMBL226898 | 0.90 | EPHX2 (0.49) | EPHX2BACE1CDK5CDK5R1NAMPT | |
| SCHEMBL4488368 | 0.90 | CCNC (0.48) | EPHX2BACE1NAMPTFLT3USP2 | |
| SCHEMBL4488363 | 0.90 | CCNC (0.48) | EPHX2BACE1NAMPTFLT3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | EPHX2 2278/4885BACE1 1615/4885CYP2C9 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.